Table 3 Comparisons of baseline characteristics of patients with and without early neurological deterioration
From: Clinical significance of D-dimer levels during acute period in ischemic stroke
|  | No END (n = 188) | END (n = 58) | P value |
|---|---|---|---|
Age, y [IQR] | 77 [68–82] | 79 [67–85] | 0.496 |
Sex, male, n (%) | 111 (59.0) | 28 (48.3) | 0.148 |
Visit time, d [IQR] | 4.0 [1.5–13.0] | 3.8 [1.5–10.0] | 0.718 |
Hypertension, n (%) | 123 (65.4) | 41 (70.7) | 0.457 |
Diabetes, n (%) | 58 (30.9) | 20 (34.5) | 0.603 |
Dyslipidemia, n (%) | 83 (44.1) | 18 (31.0) | 0.076 |
Ischemic heart disease, n (%) | 28 (14.9) | 11 (19.0) | 0.458 |
Atrial fibrillation, n (%) | 43 (22.9) | 18 (31.0) | 0.208 |
Current smoking, n (%) | 40 (21.3) | 7 (12.1) | 0.119 |
History of stroke, (%) | 50 (26.6) | 15 (25.9) | 0.912 |
Stroke mechanism, (%) | Â | Â | 0.024 |
Large artery atherosclerosis | 54 (28.7) | 20 (34.5) | 0.403 |
Small vessel occlusion | 34 (18.1) | 5 (8.6) | 0.084 |
Cardioembolism | 49 (26.1) | 18 (31.0) | 0.457 |
Other determined | 4 (2.1) | 6 (10.3) | 0.006 |
Undetermined | 41 (21.8) | 7 (12.1) | 0.102 |
Two or more | 6 (3.2) | 2 (3.4) | 0.923 |
Initial NIHSS score [IQR] | < 0.001 | ||
Use of anticoagulants, n (%) | 35 (18.6) | 13 (22.4) | 0.524 |
Hemoglobin A1c, % [IQR] | 5.9 [5.6–6.5] | 5.9 [5.6–6.6] | 0.623 |
Fasting glucose, mg/dL [IQR] | 96 [87–113] | 107 [94–126] | 0.003 |
Total cholesterol, mg/dL [IQR] | 158 [133–188] | 169 [145–199] | 0.113 |
White blood cell, x 103/uL [IQR] | 7.40 [5.78–9.37] | 8.64 [6.09–11.07] | 0.013 |
High-sensitivity CRP, mg/dL [IQR] | 0.20 [0.07–0.60] | 0.26 [0.08–1.98] | 0.199 |
Initial D-dimer, mg/L [IQR] | 1.10 [0.74–1.80] | 1.51 [1.02–3.36] | 0.001 |
Follow-up D-dimer, mg/L [IQR] | 1.11 [0.72–2.01] | 2.14 [1.20–4.26] | < 0.001 |
Change in D-dimer, mg/L [IQR] | -0.03 [-0.31 -0.33] | 0.09 [-0.78-1.71] | 0.357 |